Track MiMedx Group, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

MiMedx Group, Inc. MDXG · Stock Open MiMedx Group, Inc. in new tab

3.21 USD
P/E
99.38
EPS
-0.13
P/B
2.30
ROE
-8.53
Beta
1.18
Target Price
7.00 USD
MiMedx Group, Inc. logo

MiMedx Group, Inc.

🧾 Earnings Recap – Q3 2026

MiMedx reported mixed third-quarter trends: Surgical sales grew, while Wound Care remained pressured by Medicare reimbursement changes. The stock rose 0.5% after earnings, a roughly flat reaction.

  • Net sales were $62 million; Surgical revenue increased 9% year over year, with volume up in the mid-teens.
  • Management said Surgical growth would have been in the mid-teens excluding nearly $1 million of prior-year opportunistic sales that did not recur and higher rebate adjustments tied to promotional activity.
  • Wound Care continued to face pricing pressure, lower market volume and disruption from 2026 Medicare reimbursement changes; Wound Care Center volume grew 7% sequentially.
  • GAAP gross margin was 80%, up 11 percentage points sequentially; adjusted EBITDA was $2 million, a $10 million sequential improvement.
  • MiMedx announced a $25 million settlement and licensing agreement with one party it says infringed its patents, while two other cases remain in litigation; the Sanara acquisition faces an extended FTC review.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 24, 2027
P/E99.38
EPS-0.13
Book Value1.45
Price to Book2.30
Debt/Equity7.97
% Insiders2.141%
Growth
Revenue Growth-0.45%
Earnings Growth1.00%
Estimates
Forward P/E31.17
Forward EPS0.11
Target Mean Price7.00

DCF valuation

Model fair value for MiMedx Group, Inc. (MDXG)
Result
Sign in to run the valuation for MDXG.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
5 analysts · consensus Strong buy · mean target 7.00 USD (low 6.00, high 8.00) · as of 11 Nov 2026
Low 6.00
Mean 7.00
High 8.00
Price 3.21
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

MiMedx Group, Inc. Logo MiMedx Group, Inc. Analysis (MDXG)

United States Health Care Official Website Stock

Is MiMedx Group, Inc. a good investment? MiMedx Group, Inc. (MDXG) is currently trading at 3.21 USD. Market analysts have a consensus price target of 7.00 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 99.38. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: MiMedx Group, Inc. is expected to release its next earnings report on Feb. 24, 2027. The market consensus estimate for Forward EPS is 0.11.

Investor FAQ

Does MiMedx Group, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is MiMedx Group, Inc.?

MiMedx Group, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 24, 2027. The company currently has a trailing EPS of -0.13.

Company Profile

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.

Exchange Ticker
NMS (United States) MDXG
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
April 2, 2008 0.32
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion